Multiple Myeloma

CAR T cells are a more effective therapy if manufactured for patients with multiple myeloma prior to the onset of relapsed or refractory disease.

Autologous stem cell transplant has become safer over the years for patients with multiple myeloma and renal insufficiency.

The combination use of Darzalex with bortezomib, thalidomide, and dexamethasone was approved for transplant-eligible patients with multiple myeloma.

How much do you know about stem cell transplantation in multiple myeloma? Here's your chance to find out.

A new study suggests there is a cost and efficiency benefit to pre-emptively administrating plerixafor during stem cell collection.

Patients with multiple myeloma whose disease progresses on BCMA-targeted therapy can possibly respond to a different BCMA-targeted therapy.

Researchers looked to see how a patient's monoclonal gammopathy of undetermined significance status affects their risk for multiple myeloma.

How much do you know about thrombotic microangiopathies in multiple myeloma? Here's your chance to find out.

Older adults with multiple myeloma are not receiving the recommended care which includes bone-modifying drugs, antiviral prophylaxis, and the influenza vaccine.

New data push back against previous thinking that an individual's risk of progression from MGUS to multiple myeloma was constant.

How much do you know about toxicities associated with multiple myeloma? Here's your chance to find out.

A new study found that enrolling appropriate patients with multiple myeloma into hospice may have cost implications.

The FDA approved selinexor in combination with the corticosteroid dexamethasone for the treatment of adult patients with relapsed/refractory multiple myeloma.

Researchers conducted a study to define risk factors for cardiovascular adverse events in patients with multiple myeloma who were taking proteasome inhibitors.

The FDA approved daratumumab in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

A meta-analysis on existing data on the use of autologous stem cell transplant in older patients with newly diagnosed multiple myeloma confirmed the need for randomized controlled trials.

How much do you know about the incidence of extramedullary disease in patients with multiple myeloma? Take our latest quiz to test your knowledge.

Baseline left ventricular diastolic dysfunction may help predict the incidence of severe carfilzomib-induced cardiovascular adverse events in patients with multiple myeloma.

Results from a second clinical trial examined the use of lenalidomide treatment in patients with high-risk smoldering multiple myeloma, where the standard of care has been observation.

Researchers evaluated survival and infusion time with combination isatuximab, pomalidomide, and low-dose dexamethasone vs pomalidomide plus low-dose dexamethasone alone in relapsed or refractory multiple myeloma.

The COLUMBA trial examined the efficacy, number of infusion-related reactions, and administration time for SC vs IV daratumumab in R/R multiple myeloma.

Data from the first-in-human study of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, were presented at ASCO 2019.

New data from the CASSIOPEIA trial evaluated the use of daratumumab in addition to bortezomib/thalidomide/dexamethasone after ASCT in multiple myeloma.

Research presented at ASCO 2019 posited that multiple socioeconomic factors make a real difference in overall survival.

A phase III study tested the combination conditioning regimen of busulfan plus melphalan vs standard melphalan alone for patients with newly diagnosed multiple myeloma undergoing transplantation.

Researchers looked at survival disparities between African American and Caucasian patients with multiple myeloma.

How much do you know about the use of PET/CT imaging to manage multiple myeloma? Take our latest quiz to test your knowledge.

How knowledgeable are you about the use of proteasome inhibitors in relapsed/refractory multiple myeloma? Take our latest quiz to find out.

A phase III trial evaluated intermediate-dose cytarabine plus granulocyte-colony stimulating factor (G-CSF) vs G-CSF alone prior to autoSCT in multiple myeloma.

A 39-year-old woman with no significant medical history presented to the emergency department with progressive diffuse abdominal pain, involuntary weight loss, anemic syndrome, and limitation of mobility. What is the best treatment course to follow?